STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
Interstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD....
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2011-08-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/340 |
| _version_ | 1797862857815097344 |
|---|---|
| author | O A Koneva L P Ananyeva O B Ovsyannikova L V Teplova M N Starovoitova O V Desinova T A Nevskaya R T Alekperov E G Lyubimova L N Denisov |
| author_facet | O A Koneva L P Ananyeva O B Ovsyannikova L V Teplova M N Starovoitova O V Desinova T A Nevskaya R T Alekperov E G Lyubimova L N Denisov |
| author_sort | O A Koneva |
| collection | DOAJ |
| description | Interstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD. Objective: to study the efficiency and safety of MPM therapy in patients with SSD and clinically relevant ILD in an open-label prospective study. Subjects and methods. Ten patients with SSD (7 and 3 with its diffuse and limited forms, respectively) and ILD were given MPM in combination with glucocorticoids (mean daily dose was 10+4 mg). The mean MPM therapy duration was 11.4+1.3 months. The Rodnan total skin thickness score, flexion index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and European Scleroderma Study Group (EScSG) activity index were estimated and a 6-minute walk test (6MWT) was carried out before and after MPM therapy. Results. After therapy, the whole group showed a significant reduction in skin scores from 12.9+9.8 to 5.6+3.2 (p=0.036) and EScSG from 3.9+1.4 to 2.25+1.03 (p=0.015) and an increase in exercise tolerance from 446+155 to 535+78 m (p=0.03) as evidenced by 6MWT. The degree of flexion contractures decreased from 15+21 to 3.7+11.3 mm (p>0.05). FVC (77.8+18.7% versus 73.8+11.3%) and DLCO (45+14.4% versus 42+16.4%) were significantly unchanged. A 10% or more clinically significant fall was noted in FVC and DLCO in 3 and 1 patients, respectively. In the remaining patients, the lung functional test results remained stable. MPM tolerability was satisfactory. All the patients completed their course of treatment. Conclusion. Stabilization of lung function with higher exercise tolerance and significantly reduced skin density allow therapy with MPM in combination with low-dose glucocorticoids to be regarded as an effective and well-tolerated treatment in patients with ILD in the presence of SSD |
| first_indexed | 2024-04-09T22:26:19Z |
| format | Article |
| id | doaj.art-875411bdfd06486693fa42104018520e |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:26:19Z |
| publishDate | 2011-08-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-875411bdfd06486693fa42104018520e2023-03-22T13:45:46ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922011-08-01494162310.14412/1995-4484-2011-56280STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMAO A KonevaL P AnanyevaO B OvsyannikovaL V TeplovaM N StarovoitovaO V DesinovaT A NevskayaR T AlekperovE G LyubimovaL N DenisovInterstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD. Objective: to study the efficiency and safety of MPM therapy in patients with SSD and clinically relevant ILD in an open-label prospective study. Subjects and methods. Ten patients with SSD (7 and 3 with its diffuse and limited forms, respectively) and ILD were given MPM in combination with glucocorticoids (mean daily dose was 10+4 mg). The mean MPM therapy duration was 11.4+1.3 months. The Rodnan total skin thickness score, flexion index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and European Scleroderma Study Group (EScSG) activity index were estimated and a 6-minute walk test (6MWT) was carried out before and after MPM therapy. Results. After therapy, the whole group showed a significant reduction in skin scores from 12.9+9.8 to 5.6+3.2 (p=0.036) and EScSG from 3.9+1.4 to 2.25+1.03 (p=0.015) and an increase in exercise tolerance from 446+155 to 535+78 m (p=0.03) as evidenced by 6MWT. The degree of flexion contractures decreased from 15+21 to 3.7+11.3 mm (p>0.05). FVC (77.8+18.7% versus 73.8+11.3%) and DLCO (45+14.4% versus 42+16.4%) were significantly unchanged. A 10% or more clinically significant fall was noted in FVC and DLCO in 3 and 1 patients, respectively. In the remaining patients, the lung functional test results remained stable. MPM tolerability was satisfactory. All the patients completed their course of treatment. Conclusion. Stabilization of lung function with higher exercise tolerance and significantly reduced skin density allow therapy with MPM in combination with low-dose glucocorticoids to be regarded as an effective and well-tolerated treatment in patients with ILD in the presence of SSDhttps://rsp.mediar-press.net/rsp/article/view/340interstitial lung diseaselung involvement, systemic sclerodermamycophenolate mofetil |
| spellingShingle | O A Koneva L P Ananyeva O B Ovsyannikova L V Teplova M N Starovoitova O V Desinova T A Nevskaya R T Alekperov E G Lyubimova L N Denisov STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA Научно-практическая ревматология interstitial lung disease lung involvement, systemic scleroderma mycophenolate mofetil |
| title | STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA |
| title_full | STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA |
| title_fullStr | STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA |
| title_full_unstemmed | STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA |
| title_short | STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA |
| title_sort | study of the efficiency and safety of mycophenolate mofetil therapy in patientswith systemic scleroderma |
| topic | interstitial lung disease lung involvement, systemic scleroderma mycophenolate mofetil |
| url | https://rsp.mediar-press.net/rsp/article/view/340 |
| work_keys_str_mv | AT oakoneva studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT lpananyeva studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT obovsyannikova studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT lvteplova studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT mnstarovoitova studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT ovdesinova studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT tanevskaya studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT rtalekperov studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT eglyubimova studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma AT lndenisov studyoftheefficiencyandsafetyofmycophenolatemofetiltherapyinpatientswithsystemicscleroderma |